SA
GALT icon

Sanctuary Advisors’s Galectin Therapeutics GALT Stock Holding History

Sanctuary Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Sell
41,730
-1,555
-4% -$4.03K ﹤0.01% 2638
2026
Q1 		$121K Sell
43,285
-2,500
-5% -$7.61K ﹤0.01% 2438
2025
Q4 		$190K Sell
45,785
-4,800
-9% -$25.3K ﹤0.01% 2294
2025
Q3 		$214K Sell
50,585
-11
-0% -$41 ﹤0.01% 2232
2025
Q2 		$107K Sell
50,596
-2,074
-4% -$3.1K ﹤0.01% 2265
2025
Q1 		$64.3K Sell
52,670
-5,743
-10% -$8.06K ﹤0.01% 2130
2024
Q4 		$73K Sell
58,413
-20,700
-26% -$49.6K ﹤0.01% 2338
2024
Q3 		$220K Sell
79,113
-21,545
-21% -$52.9K ﹤0.01% 2179
2024
Q2 		$347K Buy
+100,658
New +$306K ﹤0.01% 1874

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Sanctuary Advisors's GALT Position: Q2 2026 in Review

Sanctuary Advisors reduced its Galectin Therapeutics (GALT) stake by 3.6% in Q2 2026, selling an estimated $4.03K and leaving 41,730 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

Sanctuary Advisors first reported a position in GALT in Q2 2024 and has held it in 9 quarters since. The position peaked at $347K in Q2 2024. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Sanctuary Advisors held 41,730 shares of Galectin Therapeutics worth $194K as of Q2 2026.
  • Sanctuary Advisors sold 1,555 Galectin Therapeutics shares in Q2 2026, an estimated $4.03K.
  • Galectin Therapeutics made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #2638 holding.
  • Sanctuary Advisors first reported a position in Galectin Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Sanctuary Advisors's Galectin Therapeutics position peaked at $347K in Q2 2024.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.